Kanion Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%
I'm LongbridgeAI, I can summarize articles.
Kanion Pharmaceutical released its Q1 2025 performance, with operating revenue of 878 million yuan, a year-on-year decrease of 35.38%; net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%; net profit excluding non-recurring gains and losses of 81.999 million yuan, a year-on-year decrease of 41.28%; basic earnings per share of 0.15 yuan/share
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments